Allot Communications (ALLT) Tops Q2 EPS by 2c, Slight Beat on Revenues; Offers FY18 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...)
August 6, 2018 9:27 AM EDTToday's Pre-Open Movers
Ovid Therapeutics Inc. (NASDAQ: OVID) 27% LOWER; announced that the Phase 2 STARS trial of OV101 achieved its primary endpoint of safety and tolerability. The investigational medicine showed a favorable safety profile and was well tolerated in adults and adolescents with Angelman syndrome. OV101 is the only selective extrasynaptic GABAA receptor agonist in development shown to mediate tonic inhibition, a key underlying pathophysiological mechanism of Angelman syndrome. Ovids founder, president and chief scientific officer, Matthew During, M.D., DSc, FACP, will present the data today at the 2018 Angelman Syndrome... More
Needham & Company Upgrades Allot Communications (ALLT) to Buy
August 6, 2018 5:46 AM EDTNeedham & Company upgraded Allot Communications (NASDAQ: ALLT) from Hold to Buy with a price target of $6.35.
Analyst Alex Henderson says a new tier 1 win is a major proof-point on Intensifying SaaS business. The analyst says management continues to executed against a turn-around... More
